

Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide

NUC-1031

Awa Sarr^{1,2}§, Jennifer Bré¹§, In Hwa Um¹, Tsz Huen Chan¹, Peter Mullen¹, David J.

Harrison¹, Paul A. Reynolds^{1,2*}

¹*School of Medicine, University of St Andrews, St Andrews, UK, KY16 9TF.*

²*Biomedical Sciences Research Complex, University of St. Andrews, St. Andrews, UK.*

§The authors contributed equally to this work

*Corresponding author

Email: par10@st-andrews.ac.uk

Supplementary Information




Figure S1: Dose-response curves for A2780 or MiaPaCa2 cells 4d after treatment with NUC-1031 or gemcitabine that were pre-treated when cells were plated with either DMSO, 50 μ M or 100 μ M of deoxycytidine (dCyd). Values represent mean \pm SEM (n=6).




Figure S2: (A) Cell cycle analysis of A2780 cells, post treatment with IC₅₀ of gemcitabine or NUC-1031 or DMSO (ctrl) for 2h. Horizontal axis, DNA content; vertical axis, BrdU incorporation. (B) Quantification of percentage of cell population in different phases of the cell cycle.




Fig. S3: Read coverage per sgRNA for GeCKOv2 library

Cumulative distribution of the number of reads per sgRNA in a single MiaPaCa2 experiment. Less than 1% of the sgRNAs are covered by less than 10 reads.




Figure S5: Patients were stable for less than six months, or progressive disease developed within that time (group 1), or were stable for six months or more (group 2). Tissues were immunostained for DCTPP1 and scanned images were quantified using QuPath. Histoscores for DCTPP1 expression (nucleus or cytoplasm) for group 1 vs group 2 are presented (nucleus group 1 vs group 2 $p=0.7054$, cytoplasm group 1 vs group 2 $p=0.6679$; Mann Whitney test).

MAGeCK analysis: gene ranking
 Top 30 hits Acelarin d14

id	num	neg score	neg p-value	neg fdr	neg rank	neg goodsigma	pos score	pos p-value	pos fdr	pos rank	pos goodsigma
TMEM165	6	0.89556	0.7684	0.870669	19323	0	1.70E-16	2.26E-07	0.002475	1	5
DCK	6	0.56879	0.27278	0.492317	12114	0	1.21E-10	2.26E-07	0.002475	2	4
PVCR2	6	0.99302	0.98538	0.995277	21697	0	8.59E-06	7.00E-06	0.051155	3	2
DCTP1	6	0.9554	0.89913	0.950441	20729	0	2.43E-05	3.23E-05	0.149615	4	5
SYNCRIP	6	0.12341	0.033067	0.169749	4155	2	3.03E-05	4.22E-05	0.149615	5	3
NonTargetingControlGuideForHuman_0731	2	0.99997	0.99998	0.999985	21915	0	3.17E-05	4.36E-05	0.149615	6	2
RASSF7	6	0.38171	0.1424	0.373018	8351	1	3.45E-05	4.99E-05	0.149615	7	3
NACC2	6	0.39357	0.15247	0.388383	8564	1	4.04E-05	5.62E-05	0.149615	8	3
NonTargetingControlGuideForHuman_0040	2	0.99996	0.99998	0.999985	21914	0	4.31E-05	6.14E-05	0.149615	9	2
COQ4	6	0.72927	0.48821	0.681733	15613	0	6.44E-05	0.00010233	0.168542	10	2
NonTargetingControlGuideForHuman_0737	2	0.99994	0.99996	0.999985	21913	0	6.48E-05	0.00010233	0.168542	11	2
LOC100288524	6	0.037069	0.0037808	0.047873	1723	2	6.70E-05	0.00011814	0.168542	12	3
TSPAN12	6	0.061216	0.011213	0.100332	2439	1	8.26E-05	0.00014435	0.168542	13	2
DCAF4	6	0.99166	0.98144	0.992835	21663	0	9.36E-05	0.000157	0.168542	14	5
NonTargetingControlGuideForHuman_0075	2	0.99991	0.99992	0.999985	21912	0	9.46E-05	0.00015926	0.168542	15	2
CASA	6	0.80952	0.60412	0.759572	17409	0	9.48E-05	0.00015926	0.168542	16	4
MB	6	0.31836	0.095462	0.284932	7323	1	0.00010169	0.00017055	0.168542	17	5
NonTargetingControlGuideForHuman_0341	2	0.99989	0.9999	0.999985	21911	0	0.00010952	0.00017552	0.168542	18	2
ING3	6	0.99466	0.98926	0.99745	21735	0	0.00012134	0.00019314	0.168542	19	4
PTOV1	6	0.016441	0.0015544	0.035042	933	1	0.00012154	0.00019314	0.168542	20	4
SKOR1	6	0.057705	0.0084781	0.079033	2333	1	0.00013155	0.00020489	0.168542	21	4
NonTargetingControlGuideForHuman_0124	2	0.99987	0.99987	0.999985	21910	0	0.0001338	0.0002076	0.168542	22	2
ZNF583	6	0.35839	0.1198	0.329225	7963	1	0.00013629	0.00020805	0.168542	23	3
COB37A	6	0.98104	0.95755	0.980509	21394	0	0.00013741	0.0002094	0.168542	24	4
POLA2	6	0.80588	0.5957	0.75335	17326	0	0.00013826	0.00021121	0.168542	25	4
ATXN2L	6	0.90774	0.79438	0.886342	19634	0	0.00014903	0.00021889	0.168542	26	4
ITIH4	6	0.34886	0.11698	0.326132	7792	1	0.00015444	0.00022612	0.168542	27	3
NonTargetingControlGuideForHuman_0397	2	0.99984	0.99984	0.999985	21907	0	0.00015521	0.00022657	0.168542	28	2
VPS54	6	0.40552	0.15962	0.396167	8781	1	0.0001669	0.0002469	0.168542	29	3

MAGeCK analysis: gene ranking
 Top 30 hits Acelarin d21

id	num	neg score	neg p-value	neg fdr	neg rank	neg goodsigma	pos score	pos p-value	pos fdr	pos rank	pos goodsigma
TMEM165	6	0.98768	0.927	0.942479	21555	0	2.18E-12	2.26E-07	0.00495	1	5
DCK	6	0.76661	0.38221	0.50634	16535	0	2.80E-07	2.48E-06	0.027228	2	5
NonTargetingControlGuideForHuman_0397	2	1	0.99997	0.999974	21915	0	3.70E-06	4.27E-05	0.311881	3	2
SIRPD	6	0.99413	0.96151	0.970096	21721	0	9.06E-06	0.00012808	0.589109	4	5
TPSAIN12	6	0.015437	0.00040955	0.009497	900	2	9.73E-06	0.00013441	0.589109	5	2
HCN3	6	0.51095	0.16972	0.33742	10998	1	1.50E-05	0.00019224	0.702145	6	5
POMP	6	0.6116	0.23302	0.388634	13124	0	1.92E-05	0.0002582	0.808345	7	4
NonTargetingControlGuideForHuman_0203	2	0.99996	0.99972	0.999764	21914	0	3.58E-05	0.00049313		8	2
NonTargetingControlGuideForHuman_0045	2	0.99996	0.99971	0.999764	21913	0	3.82E-05	0.00051075		9	2
DDO	6	0.26344	0.052691	0.168552	6785	1	6.27E-05	0.00074478		10	5
SLC36A1	6	0.93076	0.7074	0.76749	20198	0	6.34E-05	0.00076511		11	3
NonTargetingControlGuideForHuman_0005	2	0.99993	0.99953	0.999669	21912	0	7.03E-05	0.00087399		12	2
ADORA1	6	0.012939	0.00030338	0.008504	780	2	7.29E-05	0.00090607		13	3
MEMO1	6	0.7397	0.34785	0.477227	15957	0	8.26E-05	0.0010624		14	2
NonTargetingControlGuideForHuman_0731	2	0.99991	0.99934	0.999519	21911	0	9.17E-05	0.0012232		15	2
GLDC	6	0.54405	0.1885	0.348123	11662	1	0.0001866	0.0015476		16	4
WFDG9	6	0.93738	0.73245	0.788294	20355	0	0.00012154	0.0016072		17	2
NonTargetingControlGuideForHuman_0476	2	0.99987	0.99905	0.999283	21910	0	0.00013305	0.001834		18	2
NonTargetingControlGuideForHuman_0075	2	0.99986	0.99898	0.999249	21909	0	0.0001414	0.0019755		19	2
ZNF565	6	0.93562	0.72376	0.780403	20319	0	0.00014291	0.0020021		20	2
C7orf49	6	0.45745	0.13385	0.294779	9951	1	0.00014365	0.0020252		21	2
THAP5	6	0.99985	0.99887	0.999193	21908	0	0.00015071	0.0021508		22	6
EP515L1	6	0.16916	0.025647	0.101609	5454	1	0.00015274	0.0021625		23	3
NonTargetingControlGuideForHuman_0341	2	0.99984	0.99884	0.999193	21907	0	0.00015887	0.0022529		24	2
KIAA2018	6	0.20367	0.027633	0.101609	5952	1	0.0001589	0.0022529		25	3
NonTargetingControlGuideForHuman_0058	2	0.99984	0.99882	0.999193	21906	0	0.00016277	0.0023199		26	2
PORCN	6	0.2978	0.063158	0.186469	7296	1	0.0001669	0.0023807		27	2
CMA1	6	0.73834	0.34774	0.477227	15930	0	0.00017015	0.00248		28	2
NonTargetingControlGuideForHuman_0870	2	0.99982	0.99866	0.999118	21905	0	0.00018104	0.0026527		29	2

MAGeCK analysis: gene ranking
 Top 30 hits Gemcitabine d14

id	num	neg score	neg p-value	neg fdr	neg rank	neg goodsgrna	pos score	pos p-value	pos fdr	pos rank	pos goodsgrna
PPP1R32	6	0.034286	0.0026653	0.042143	1269	1	3.39E-06	2.26E-07	0.00015	1	3
hsa-mir-4711	4	0.92423	0.87125	0.945311	20198	0	6.34E-06	2.26E-07	0.00015	2	3
NCOA3	6	0.98785	0.98645	0.999362	21631	0	8.47E-06	2.26E-07	0.00015	3	4
CENPE	6	0.91379	0.85747	0.941615	19944	0	1.52E-05	2.26E-07	0.00015	4	4
UGGT2	6	0.98817	0.98678	0.999369	21638	0	1.61E-05	2.26E-07	0.00015	5	3
ARL1	6	0.44975	0.22345	0.50741	9644	0	2.43E-05	2.26E-07	0.00015	6	1
hsa-mir-548h-5	3	0.99888	0.99966	0.999991	21887	0	3.94E-05	2.26E-07	0.00015	7	2
UBXN2A	6	0.87911	0.79828	0.910972	19200	0	5.76E-05	2.26E-07	0.00015	8	2
NADK2	6	0.092507	0.01462	0.139671	2260	1	7.11E-05	2.26E-07	0.00015	9	2
CLEC19A	6	0.41226	0.18752	0.4618	8836	0	7.29E-05	2.26E-07	0.00015	10	1
PKP4	6	0.9855	0.98288	0.99886	21557	0	7.36E-05	2.26E-07	0.00015	11	4
BGLAP	6	0.27199	0.084905	0.311325	5808	0	9.25E-05	2.26E-07	0.00015	12	3
SHF	6	0.68658	0.50439	0.74486	14810	0	0.00011002	2.26E-07	0.00015	13	4
PDDC1	6	0.9164	0.86066	0.941615	20011	0	0.00012154	2.26E-07	0.00015	14	1
LPPR1	6	0.7502	0.59838	0.806785	16252	0	0.00012822	2.26E-07	0.00015	15	4
LRRC16B	6	0.83209	0.72435	0.874568	18145	0	0.00012888	2.26E-07	0.00015	16	3
MILR1	6	0.16825	0.03779	0.218891	3695	1	0.00013419	2.26E-07	0.00015	17	3
PTOV1	6	0.18487	0.044805	0.225685	4019	1	0.00017015	2.26E-07	0.00015	18	1
TUBA1B	6	0.25114	0.068054	0.274839	5375	1	0.0001829	2.26E-07	0.00015	19	3
hsa-mir-3143	4	0.99962	0.99992	0.999991	21907	0	0.00019384	2.26E-07	0.00015	20	3
RBBP8	6	0.1964	0.045191	0.225685	4260	1	0.00020858	2.26E-07	0.00015	21	2
C1orf141	6	0.23063	0.053314	0.232297	4945	1	0.00021876	2.26E-07	0.00015	22	1
NOLC1	6	0.36999	0.1587	0.437027	7939	0	0.00026737	2.26E-07	0.00015	23	1
FAM13A	6	0.99213	0.99272	0.999991	21737	0	0.00028476	2.26E-07	0.00015	24	3
BYES	6	0.81611	0.70444	0.866016	17787	0	0.00031598	2.26E-07	0.00015	25	1
PCDH18	6	0.87186	0.78798	0.906469	19036	0	0.00034594	2.26E-07	0.00015	26	3
TMEM243	6	0.45067	0.22573	0.50904	9665	0	0.00036458	2.26E-07	0.00015	27	1
TNFRSF25	6	0.1258	0.028319	0.20003	2880	1	0.00037039	2.26E-07	0.00015	28	3
hsa-mir-3195	4	0.33703	0.12538	0.378989	7247	0	0.00037246	2.26E-07	0.00015	29	2

MAGeCK analysis: gene ranking
 Top 30 hits Gemcitabine d21

id	num	neg score	neg p-value	neg fdr	neg rank	neg goodsgma	pos score	pos p-value	pos fdr	pos rank	pos goodsgma
TSC2	6	0.93806	0.83211	0.895286	20360	0	6.01E-06	2.26E-07	0.00495	1	4
CRYGC	6	0.93828	0.83225	0.895286	20372	0	1.97E-05	1.13E-06	0.008663	2	4
ATRNL1	6	0.043646	0.00055186	0.008446	1430	1	2.43E-05	1.58E-06	0.008663	3	1
SH3BP4	6	0.53277	0.21048	0.409668	11242	0	2.94E-05	1.58E-06	0.008663	4	4
hsa-mir-6727	4	0.6142	0.31463	0.529915	12973	0	4.86E-05	2.48E-06	0.010891	5	1
MAPK5	6	0.98361	0.95938	0.978212	21493	0	7.11E-05	3.39E-06	0.011386	6	2
hsa-mir-1254-2	4	0.10667	0.0070364	0.060403	2481	1	0.00010817	4.29E-06	0.011386	7	2
NonTargetingControlGuideForHuman_0555	2	0.99988	0.99996	0.99996	21911	0	0.00011641	4.74E-06	0.011386	8	2
hsa-mir-1265	4	0.99997	0.99999	1	21914	0	0.00011646	4.74E-06	0.011386	9	3
CDH20	6	0.44623	0.14132	0.331057	9355	0	0.00011803	5.20E-06	0.011386	10	4
LHX6	6	0.90563	0.75886	0.849053	19585	0	0.00012154	6.10E-06	0.012151	11	1
OGN	6	0.24413	0.034297	0.144563	5108	1	0.00017015	1.20E-05	0.014407	12	1
MOB1A	6	0.10432	0.0069876	0.060403	2442	1	0.00017699	1.20E-05	0.014407	13	3
hsa-mir-3192	4	0.76671	0.50427	0.675986	16342	0	0.00017825	1.20E-05	0.014407	14	1
HFM1	6	0.96551	0.91266	0.95012	21051	0	0.00017962	1.20E-05	0.014407	15	3
OR5R1	6	0.41494	0.11795	0.297278	8693	0	0.00018167	1.20E-05	0.014407	16	2
FUT1	6	0.43605	0.13047	0.31136	9130	0	0.00020359	1.38E-05	0.014407	17	3
IMPA1	6	0.23495	0.033543	0.144563	4919	1	0.00021765	1.47E-05	0.014407	18	2
NOTUM	6	0.14073	0.015556	0.101451	3094	1	0.00021876	1.47E-05	0.014407	19	1
GPX3	6	0.96943	0.92281	0.956463	21144	0	0.00026082	1.97E-05	0.014407	20	2
TRIM21	6	0.84442	0.62597	0.75589	18146	0	0.00026283	1.97E-05	0.014407	21	3
NUM1	6	0.14411	0.015614	0.101451	3156	1	0.00027401	2.01E-05	0.014407	22	2
SOC2	6	0.14287	0.015562	0.101451	3136	1	0.00029533	2.10E-05	0.014407	23	4
HMGCS2	6	0.80267	0.55789	0.711814	17170	0	0.00030053	2.46E-05	0.014407	24	4
LRCH2	6	0.46042	0.15653	0.352398	9663	0	0.00030157	2.46E-05	0.014407	25	3
NonTargetingControlGuideForHuman_0150	2	0.99969	0.99984	1	21909	0	0.00030506	2.51E-05	0.014407	26	2
hsa-mir-145	4	0.94144	0.84493	0.905851	20441	0	0.00031241	2.51E-05	0.014407	27	3
BCOR	6	0.28064	0.046821	0.173201	5871	0	0.00031598	2.51E-05	0.014407	28	1
hsa-mir-4529	4	0.79585	0.54835	0.705037	17010	0	0.000321	2.55E-05	0.014407	29	3

Table S1: MAGeCK analysis gene ranking for NUC-1031 and gemcitabine at d14 and d21.

Primers PCR#1	Primer Sequences	Purification	Synthesis scale (μM)
v2Adaptor_F (Forward)	5'- AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTTCG -3'	HPLC (High performance Liquid chromatography)	0.05
v2Adaptor_R (Reverse)	5'- TCTACTATTCTTTCCCTGCACTGTTGTGGGCGATGTGCGCTCTG -3'	HPLC	0.05

Primers PCR2	Primer Sequences	Purification	Synthesis scale (μM)
Illumina F1	5'-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTAAGTAGAGTCTTGTGGAAAGGACGAAACACCG-3'	HPLC	0.05
Illumina F2	5'-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTATACACGATCTTGTGGAAAGGACGAAACACCG-3'	HPLC	0.05
Illumina F3	5'-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGATCGCGCGTCTTGTGGAAAGGACGAAACACCG-3'	HPLC	0.05
Illumina F4	5'-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCGATCATGATCGTCTTGTGGAAAGGACGAAACACCG-3'	HPLC	0.05
Illumina R1	5'-CAAGCAGAAGACGGCATAACGAGATAAGTAGAGGTGACTGGAGTTCA GACGTGTGCTCTCCGATCTTTCTACTATTCTTTCCCTGCACTGT-3'	HPLC	0.05
Illumina R2	5'-CAAGCAGAAGACGGCATAACGAGATACACGATCGTGACTGGAGTTCA GACGTGTGCTCTCCGATCTATTCTACTATTCTTTCCCTGCACTGT-3'	HPLC	0.05
Illumina R3	5'-CAAGCAGAAGACGGCATAACGAGATCGCGCGTGTGACTGGAGTTCA GACGTGTGCTCTCCGATCTGATTCTACTATTCTTTCCCTGCACTGT-3'	HPLC	0.05
Illumina R4	5'-CAAGCAGAAGACGGCATAACGAGATCATGATCGGTGACTGGAGTTCA GACGTGTGCTCTCCGATCTCGATTCTACTATTCTTTCCCTGCACTGT-3'	HPLC	0.05

	Sample	Forward primer	Reverse primer
1	Replicate 1: Baseline	Illumina F1	Illumina R1
2	Replicate 1: Day 14 Control	Illumina F1	Illumina R2
3	Replicate 1: Day 14 Gemcitabine	Illumina F1	Illumina R3
4	Replicate 1: Day 14 Acelarin	Illumina F1	Illumina R4
5	Replicate 1: Day 21 Control	Illumina F2	Illumina R1
6	Replicate 1: Day 21 Gemcitabine	Illumina F2	Illumina R2
7	Replicate 1: Day 21 Acelarin	Illumina F2	Illumina R3
8	Replicate 2: Baseline	Illumina F4	Illumina R4
9	Replicate 2: Day 14 Control	Illumina F3	Illumina R1
10	Replicate 2: Day 14 Gemcitabine	Illumina F3	Illumina R2
11	Replicate 2: Day 14 Acelarin	Illumina F3	Illumina R3
12	Replicate 2: Day 21 Control	Illumina F3	Illumina R4
13	Replicate 2: Day 14 Gemcitabine	Illumina F4	Illumina R1
14	Replicate 2: Day 14 Acelarin	Illumina F4	Illumina R2

PCR#1 Conditions			
Initial denaturation	95°C	2 min	1 cycle
Denaturation	95°C	10-20 s	24 cycles
Annealing	60°C	20s	
Elongation	72°C	30s	1 cycle
Final extension	72°C	3 min	
	END		

PCR#2 Conditions			
Initial denaturation	95°C	2 min	1 cycle
Denaturation	95°C	15 s	18 cycles
Annealing	50°C	20s	
Elongation	72°C	30s	1 cycle
Final extension	72°C	3 min	
	END		

Table S2: PCR primers and conditions


Characteristics	Number of patients	Per cent %
Gender	85	100
Male	46	54
Female	39	46
Age (years)		
Median	66	-
Range	43 - 84	-
Pathologic stage		
T1	3	3.5
T2	6	7
T3	74	87
T4	2	2.5
N0	15	17.5
N1	68	80
NK	2	2.5
MX	31	36.5
M1	2	2.5
NK	52	61
Tumour differentiation		
Moderate	36	42.5
moderate-poor	11	13
Poor	28	33
well	10	11.5
Treatment		
No chemotherapy	19	22.5
Gemcitabine	24	28
Chemotherapy	14	16.5
Not known	28	33

Table S3: TMA details of pancreatic cancer cohort


Category	Subcategory	Total collective (%)
Sex	Female	27 (72.97)
	Male	10 (27.03)
Age		31 – 83 median = 56
Tumour type	Ovary	10 (27.03)
	Colon	6 (16.22)
	Oesophageal	3 (8.11)
	Breast	3 (8.11)
	Lung	2 (5.4)
	Endometrium	2 (5.4)
	Pancreas	2 (5.4)
	Biliary	2 (5.4)
	Mesothelioma	2 (5.4)
	Uterine carcinoma	1 (2.7)
	Osteosarcoma	1 (2.7)
	Cervix	1 (2.7)
	Adrenal	1 (2.7)
	Anal	1 (2.7)
Prior gemcitabine	Yes	14 (37.84)
	No	23 (62.16)
RECIST	Partial response (unconfirmed)	2 (5.4)
	Stable disease	25 (67.57)
	Progressive disease	10 (27.03)

Table S4: pan-cancer phase I cohort details


Uncropped gel blots:



Blots from Fig. 3.



Blots from Fig. 4.



Blots from Fig. 5.